Lupus-associated toxic epidermal necrolysis: A novel manifestation of lupus?

Journal of the American Academy of Dermatology

Volumn 48, Issue 4, 2003, Pages 525-529

  Mandelcorn, Rochelle ^a   Shear, Neil H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ENALAPRIL; GLIBENCLAMIDE; IMMUNOGLOBULIN; PREDNISONE; RANITIDINE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DYSPEPSIA; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECURRENT DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 0037381772     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.107     Document Type: Article

References (20)

1. Fritsch PO, Ruiz-Maldonaldo R. Stevens-Johnson syndrome-toxic epidermal necrolysis. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 644-54.
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
3. Bielsa I, Herrero C, Font J, Mascaro JM. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol 1987;16:1265-7.
4. Burge SM, Dawber RP. Stevens-Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus. J Am Acad Dermatol 1985;13:665-6.
5. Fritsch PO, Ruiz-Maldonaldo R. Erythema multiforme. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 636-44.
6. Rowell NR, Beck NJ, Anderson JR, Lupus erythematosus and erythema multiforme-like lesions. Arch Dermatol 1963;88:176-80.
7. Zeitouni NC, Funaro D, Cloutier RA, Gagne E, Claveau J. Redefining Rowell's syndrome. Br J Dermatol 2000;142:343-6.
8. Miralles ES, Nunez M, del Olmo N, Ledo A, Ranitidine-related toxic epidermal necrolysis in a patient with idiopathic thrombocytopenic purpura. J Am Acad Dermatol 1995;32:133-4.
9. Velez A, Moreno JC, Second case of ranitidine-related toxic epidermal necrolysis in a patient with idiopathic thrombocytopenic purpura. J Am Acad Dermatol 2000;42:305.
10. Yell JA, Wojnarowska F. Bullous skin disease in lupus erythematosus. Lupus 1997;6:112-21.
11. Sontheimer RD. Lupus erythematosus. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, et al, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 1993-2009.
12. Mascaro JM, Herrero C, Hausmann G. Uncommon cutaneous manifestations of lupus erythematosus. Lupus 1997;6:122-31.
13. Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol 2000;41:234-7.
14. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-3.
15. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999;8:705-12.
16. Andrade F, Casciola-Rosen L, Rosen A. Apoptosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:215-27.
17. Pablos JL, Santiago B, Galindo M, Carreira PE, Ballestin C, Gomez-Reino JJ. Keratinocyte apoptosis and p53 expression in cutaneous LE and dermatomyositis. J Pathol 1999;188:63-8.
18. Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 2001;144:958-66.
19. Cameron R, Feuer G. The effect of drugs and toxins on the process of apoptosis. Drug Metabol Drug Interact 2001;18:1-32.
20. Planey SL, Litwack G. Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 2000;279:307-12.